[go: up one dir, main page]

NO20076093L - Substituerte amidderivater som proteinkinaseinhibitorer - Google Patents

Substituerte amidderivater som proteinkinaseinhibitorer

Info

Publication number
NO20076093L
NO20076093L NO20076093A NO20076093A NO20076093L NO 20076093 L NO20076093 L NO 20076093L NO 20076093 A NO20076093 A NO 20076093A NO 20076093 A NO20076093 A NO 20076093A NO 20076093 L NO20076093 L NO 20076093L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase inhibitors
amide derivatives
substituted amide
diseases
Prior art date
Application number
NO20076093A
Other languages
English (en)
Norwegian (no)
Inventor
Steven Bellon
Mark H Norman
Tae-Seong Kim
Ning Xi
Jean-Christophe Harmange
Amico Derin C D
Kevin Yang
Shon Booker
Deborah Choquette
Russell Graceffa
Daniel La
Michele Potashman
David Bauer
Alessandro Boezio
Angelo Noel D
Celia Dominguez
Ingrid M Fellows
Julie Germain
Satoko Hirai
Matthew Lee
Original Assignee
Usroveto Philip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usroveto Philip filed Critical Usroveto Philip
Publication of NO20076093L publication Critical patent/NO20076093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
NO20076093A 2005-04-27 2007-11-26 Substituerte amidderivater som proteinkinaseinhibitorer NO20076093L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67580505P 2005-04-27 2005-04-27
PCT/US2006/016344 WO2006116713A1 (en) 2005-04-27 2006-04-27 Substituted amide derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20076093L true NO20076093L (no) 2008-01-25

Family

ID=36617399

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076093A NO20076093L (no) 2005-04-27 2007-11-26 Substituerte amidderivater som proteinkinaseinhibitorer

Country Status (34)

Country Link
US (3) US7858623B2 (el)
EP (1) EP1881976B1 (el)
JP (1) JP5463033B2 (el)
KR (1) KR20080004617A (el)
CN (1) CN101248059A (el)
AR (1) AR054262A1 (el)
AU (1) AU2006239216B2 (el)
BR (1) BRPI0608097A2 (el)
CA (1) CA2605680C (el)
CR (1) CR9475A (el)
CY (1) CY1113324T1 (el)
DK (1) DK1881976T3 (el)
EA (1) EA013231B1 (el)
ES (1) ES2396219T3 (el)
GT (1) GT200600181A (el)
HK (1) HK1116161A1 (el)
HN (1) HN2006016313A (el)
HR (1) HRP20121069T1 (el)
IL (1) IL186526A (el)
JO (1) JO2787B1 (el)
MX (1) MX2007013216A (el)
MY (1) MY177111A (el)
NO (1) NO20076093L (el)
NZ (1) NZ562595A (el)
PE (1) PE20061436A1 (el)
PL (1) PL1881976T3 (el)
PT (1) PT1881976E (el)
RS (1) RS52596B (el)
SI (1) SI1881976T1 (el)
TW (1) TWI378094B (el)
UA (1) UA93375C2 (el)
UY (1) UY29503A1 (el)
WO (1) WO2006116713A1 (el)
ZA (1) ZA200708775B (el)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
KR101257343B1 (ko) 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
SI1928454T1 (sl) 2005-05-10 2015-01-30 Intermune, Inc. Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
CN101522687A (zh) 2006-01-30 2009-09-02 阿雷生物药品公司 用于癌症治疗的杂二环噻吩化合物
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
JP2009537632A (ja) * 2006-05-19 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
WO2008035209A2 (en) * 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP2032538A2 (en) * 2006-06-08 2009-03-11 Array Biopharma, Inc. Quinoline compounds and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP5276005B2 (ja) 2006-11-08 2013-08-28 ブリストル−マイヤーズ スクイブ カンパニー ピリジノン化合物
AU2007338795B2 (en) * 2006-12-20 2012-07-19 Amgen Inc. Substituted heterocycles and methods of use
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
MX2009006543A (es) 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
MX2010002427A (es) * 2007-08-29 2010-03-30 Methylgene Inc Inhibidores de actividad de la proteina tirosina cinasa.
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
EP2220078B1 (en) * 2007-10-29 2013-05-22 Amgen, Inc Benzomorpholine derivatives and methods of use
CN101918391B (zh) 2007-11-06 2013-06-05 阿斯利康(瑞典)有限公司 一些2-吡嗪酮衍生物和它们在制备嗜中性白细胞弹性蛋白酶抑制剂中的用途
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona
ES2398335T3 (es) 2008-01-23 2013-03-15 Bristol-Myers Squibb Company Compuestos de 4-piridinona y su uso para el cáncer
CN102161663B (zh) 2008-03-05 2014-03-19 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2009149188A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
NZ605292A (en) 2008-08-20 2014-06-27 Zoetis Services Llc Pyrrolo[2,3-d]pyrimidine compounds
AU2009298888A1 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
CA2738583A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
CA2745165A1 (en) * 2008-12-05 2010-06-10 Merck Sharp & Dohme Corp. Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
WO2010068794A2 (en) * 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
AU2010271105C1 (en) 2009-01-12 2014-08-21 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
US8367836B2 (en) * 2009-04-27 2013-02-05 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
RU2012109233A (ru) * 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
ES2528948T3 (es) * 2009-09-21 2015-02-13 Chemocentryx, Inc. Derivados de pirrolidinona carboxamida como moduladores de quemerina-R (ChemR23)
AU2010302420B2 (en) 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
CN102822167A (zh) 2010-01-04 2012-12-12 埃南蒂亚有限公司 用于制备利伐沙班的方法及其中间体
CN102212062B (zh) * 2010-04-02 2015-04-29 广东东阳光药业有限公司 氨基酯类衍生物及其盐和使用方法
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND ITS USE FOR THE TREATMENT OF EYE DISEASES
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
WO2012008563A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012034132A2 (en) 2010-09-10 2012-03-15 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
BR112013014708B1 (pt) * 2011-02-28 2021-10-19 Sunshine Lake Pharma Co., Ltd. Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2742043B1 (en) * 2011-08-10 2016-10-26 Merck Patent GmbH Pyrido-pyrimidine derivatives
US9428472B2 (en) 2011-08-16 2016-08-30 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
SG11201402531XA (en) * 2011-11-22 2014-08-28 Deciphera Pharmaceuticals Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
JP6192708B2 (ja) 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
CN104603130B (zh) 2012-04-13 2018-04-27 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
CN103420986A (zh) * 2012-05-18 2013-12-04 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
JP6181172B2 (ja) * 2012-06-26 2017-08-16 バイエル・ファルマ・アクティエンゲゼルシャフト アンドロゲン受容体拮抗薬としてのｎ−［４−（キノリン−４−イルオキシ）シクロヘキシル（メチル）］（ヘテロ）アリールカルボキサミド類、医薬品としてのその製造および使用
CN104507930B (zh) * 2012-06-29 2017-10-10 贝达药业股份有限公司 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
TWI520962B (zh) 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103565653B (zh) * 2012-07-16 2017-01-25 广东东阳光药业有限公司 取代的吡唑酮化合物及其使用方法和用途
WO2014022116A2 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
TWI570116B (zh) * 2012-08-03 2017-02-11 習寧 取代的吡唑酮化合物及其使用方法
KR101350006B1 (ko) * 2012-09-06 2014-02-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
UA119136C2 (uk) 2012-10-15 2019-05-10 Епізайм, Інк. Заміщені фенілкарбоксамідні сполуки
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
MX371382B (es) 2013-03-15 2020-01-28 Aerpio Therapeutics Inc Composiciones, formulaciones y metodos para tratar enfermedades oculares.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6464395B2 (ja) * 2013-06-06 2019-02-06 リード ディスカヴァリー センター ゲーエムベーハーＬｅａｄ Ｄｉｓｃｏｖｅｒｙ Ｃｅｎｔｅｒ ＧｍｂＨ マクロファージを刺激する１受容体ｍｓｔｒ１のキノリン阻害剤
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
SG11201602269QA (en) 2013-10-16 2016-04-28 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
CN104974162B (zh) * 2014-04-09 2018-09-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
US9718841B2 (en) * 2014-04-22 2017-08-01 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN107667101B (zh) * 2015-04-14 2021-07-30 奎利恩特有限公司 作为tam rtk抑制剂的喹啉衍生物
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
ES2769124T3 (es) * 2015-07-20 2020-06-24 Betta Pharmaceuticals Co Ltd Forma cristalina de maleato de derivados de piridina condensados y usos de la misma
CN106632254B (zh) * 2015-11-02 2019-03-01 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
CN106632253B (zh) * 2015-11-02 2019-03-22 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
WO2017083789A1 (en) * 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
JP6921818B2 (ja) * 2015-11-14 2021-08-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
CN107286140A (zh) * 2016-04-12 2017-10-24 上海医药工业研究院 取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
WO2017198196A1 (zh) * 2016-05-18 2017-11-23 王子厚 具有抗肿瘤活性的喹啉衍生物
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
PT3552017T (pt) 2016-12-09 2022-05-04 Denali Therapeutics Inc Compostos úteis como inibidores de ripk1
JP6605763B2 (ja) 2017-01-26 2019-11-13 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
CN110573505B (zh) 2017-04-27 2023-04-11 阿斯利康(瑞典)有限公司 C5-苯胺喹唑啉化合物及其在治疗癌症中的用途
EP3655406A1 (en) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. NOVEL FUNGICIDE HETEROCYCLIC COMPOUNDS
WO2019048989A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. NOVEL FUNGICIDE HETEROCYCLIC COMPOUNDS
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3741752A4 (en) * 2018-01-17 2021-05-26 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
JP6955630B2 (ja) 2018-03-08 2021-10-27 ウェルマーカー・バイオ・カンパニー・リミテッドＷｅｌｌｍａｒｋｅｒ Ｂｉｏ ＣＯ．， Ｌｔｄ． チエノピリジン誘導体およびそれを含む医薬組成物
SG11202009280RA (en) * 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
CN110372666B (zh) * 2018-04-13 2022-11-08 华东理工大学 喹唑啉类化合物作为egfr三突变抑制剂及其应用
CN110511218A (zh) * 2018-05-21 2019-11-29 中国科学院上海药物研究所 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
CN111295380B (zh) * 2018-06-01 2020-11-20 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物
CN108727386A (zh) * 2018-07-16 2018-11-02 广州医科大学 一种吡唑并嘧啶类化合物及其制备方法和用途
WO2020038460A1 (zh) * 2018-08-24 2020-02-27 南京药捷安康生物科技有限公司 一种新型的喹啉衍生物抑制剂
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
US20220289679A1 (en) 2019-07-29 2022-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN114391012A (zh) * 2019-08-02 2022-04-22 美国安进公司 作为kif18a抑制剂的吡啶衍生物
WO2021023888A1 (en) 2019-08-08 2021-02-11 B.C.I. Pharma Isoquinoline derivatives as protein kinase inhibitors
EP3819300A4 (en) 2019-09-06 2021-11-24 Wellmarker Bio Co., Ltd. THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
US20220315579A1 (en) * 2019-09-26 2022-10-06 Exelixis, Inc. Pyridone compounds and methods of use
CN113121429B (zh) * 2020-01-15 2024-04-26 鲁南制药集团股份有限公司 一种c-Met激酶抑制剂及其制备方法和应用
EP4110779A1 (en) * 2020-02-24 2023-01-04 Exelixis, Inc. Compounds and methods of use
CN111440174B (zh) * 2020-04-02 2021-07-09 广州医科大学 一种吡啶酰胺类化合物及其制备方法与应用
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
US20240174683A1 (en) 2021-02-05 2024-05-30 Bayer Aktiengesellschaft Map4k1 inhibitors
AU2022257621A1 (en) 2021-04-13 2023-11-23 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
IL309175A (en) 2021-06-18 2024-02-01 Aligos Therapeutics Inc Methods and preparations for targeting PD-L1
TW202315628A (zh) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
CN113999205B (zh) * 2021-12-13 2023-09-15 辽宁大学 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN116283920B (zh) * 2023-03-31 2024-04-16 贵州医科大学 2,4-二取代吡啶类化合物及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
JPS63145272A (ja) 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JPH08193070A (ja) * 1995-01-11 1996-07-30 Mitsubishi Chem Corp ２−イミダゾリジノン誘導体及びそれを有効成分とする除草剤、並びにその製造中間体
WO1996023774A1 (fr) 1995-01-31 1996-08-08 Zenyaku Kogyo Kabushiki Kaisha Derives de thioquinoline
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
GB9505702D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd Fungicidal compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
EP0802914B1 (en) 1995-11-14 2001-06-06 PHARMACIA & UPJOHN S.p.A. Aryl- and heteroaryl- purine and pyridopyrimidine derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
JP4495257B2 (ja) 1997-02-19 2010-06-30 バーレツクス ラボラトリーズ インコーポレーテツド Ｎｏｓ抑制剤としてのｎ−複素環誘導体
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2328973A1 (en) 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
DE69924500T2 (de) 1998-08-21 2006-02-09 Parker Hughes Institute, St. Paul Chinazolinderivate
ES2281591T3 (es) 1999-01-22 2007-10-01 Kirin Beer Kabushiki Kaisha Derivados de n-((quinolinil)oxil)-fenil)-urea y de n-((quinazolinil)oxil)-fenil)-urea con actividad antitumoral.
SK288378B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Použitie chinazolínových derivátov ako inhibítorov angiogenézy
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
BR0010599A (pt) 1999-04-12 2002-02-13 Aventis Pharma Ltd Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina
SK3832002A3 (en) 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
KR20030009391A (ko) 2000-03-17 2003-01-29 브리스톨-마이어스 스퀴브 파마 컴파니 기질 금속단백분해효소 및 ＴＮＦ-α의 억제제인 시클릭β-아미노산 유도체
WO2001070734A2 (en) 2000-03-17 2001-09-27 Bristol-Myers Squibb Pharma Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
AU2001268545A1 (en) 2000-06-21 2002-01-08 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
JP4105949B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
EP1975620A3 (en) 2001-03-02 2008-12-24 GPC Biotech AG Three hybrid assay system
DE60211317T2 (de) 2001-03-23 2007-04-12 Bayer Corp. Rho-kinase inhibitoren
WO2002098426A1 (en) 2001-06-06 2002-12-12 Aventis Pharma Limtied Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
AU2002313249B2 (en) 2001-06-22 2008-08-21 Kirin Pharma Kabushiki Kaisha Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
WO2002000004A2 (en) 2001-07-05 2002-01-03 Telefonaktiebolaget Lm Ericsson (Publ) Detrimental latch-up avoidans in digital circuits
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
MXPA04004219A (es) 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
PT1474420E (pt) 2002-02-01 2012-05-10 Astrazeneca Ab Compostos de quinazolina
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2004037784A2 (en) 2002-10-21 2004-05-06 Irm Llc Pyrrolidones with anti-hiv activity
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
CA2517166A1 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists
WO2004083235A2 (en) 2003-03-19 2004-09-30 Exelixis Inc. Tie-2 modulators and methods of use
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
JP4750701B2 (ja) 2003-07-07 2011-08-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング マロンアミド誘導体
BRPI0414011A (pt) 2003-08-29 2006-10-24 Pfizer naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
AU2004281154A1 (en) 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
AU2005206571B8 (en) 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7523317B2 (en) 2004-04-29 2009-04-21 International Business Machines Corporation Computer grid access management system
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
HK1116161A1 (en) 2008-12-19
US8088794B2 (en) 2012-01-03
CR9475A (es) 2008-03-07
IL186526A0 (en) 2008-01-20
PT1881976E (pt) 2012-11-21
MY177111A (en) 2020-09-07
NZ562595A (en) 2011-02-25
EA013231B1 (ru) 2010-04-30
CA2605680A1 (en) 2006-11-02
ZA200708775B (en) 2008-06-25
JO2787B1 (en) 2014-03-15
CN101248059A (zh) 2008-08-20
US7858623B2 (en) 2010-12-28
US20120070413A1 (en) 2012-03-22
ES2396219T3 (es) 2013-02-20
TWI378094B (en) 2012-12-01
EP1881976B1 (en) 2012-10-17
UY29503A1 (es) 2006-11-30
AU2006239216A1 (en) 2006-11-02
UA93375C2 (ru) 2011-02-10
WO2006116713A1 (en) 2006-11-02
BRPI0608097A2 (pt) 2009-11-10
PL1881976T3 (pl) 2013-03-29
AR054262A1 (es) 2007-06-13
TW200716596A (en) 2007-05-01
EA200702339A1 (ru) 2008-04-28
KR20080004617A (ko) 2008-01-09
US8685983B2 (en) 2014-04-01
DK1881976T3 (da) 2013-02-04
SI1881976T1 (sl) 2013-01-31
AU2006239216B2 (en) 2012-11-29
RS52596B (en) 2013-04-30
MX2007013216A (es) 2007-12-12
EP1881976A1 (en) 2008-01-30
JP5463033B2 (ja) 2014-04-09
US20110118252A1 (en) 2011-05-19
IL186526A (en) 2012-10-31
US20080312232A1 (en) 2008-12-18
CA2605680C (en) 2012-10-16
HN2006016313A (es) 2010-06-08
JP2008539275A (ja) 2008-11-13
GT200600181A (es) 2007-05-08
PE20061436A1 (es) 2007-02-08
HRP20121069T1 (hr) 2013-01-31
CY1113324T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20063693L (no) Forbindelse og metode for anvendelse
NO20070917L (no) Imidazotriaziner som protein-kinaseinhibitorer
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EA200801372A1 (ru) Способы получения замещенных пиримидинов
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20064895L (no) 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
MX2021015262A (es) Inhibidores de prmt5.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application